How do you administer this medicine?
What is Ciprofloxacin Aristo?
Ciprofloxacin Aristo is an antibiotic in a group of drugs called fluoroquinolones (flor-o-KWIN-o-lones). Ciprofloxacin Aristo fights bacteria in the body.
Ciprofloxacin Aristo is used to treat different types of bacterial infections. Ciprofloxacin Aristo is also used to treat people who have been exposed to anthrax.
Ciprofloxacin Aristo may also be used for purposes not listed in this medication guide.
Ciprofloxacin Aristo indications
Ciprofloxacin Aristo Injection, USP in 5% Dextrose is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the conditions and patient populations listed below when the intravenous administration is needed.
Urinary Tract Infections
Ciprofloxacin Aristo Injection, USP in 5% Dextrose is indicated in adult patients for treatment of urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, Providencia rettgeri, Morganella morganii, Citrobacter koseri, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus epidermidis, Staphylococcus saprophyticus, or Enterococcus faecalis.
Lower Respiratory Tract Infections
Ciprofloxacin Aristo Injection, USP in 5% Dextrose is indicated in adult patients for treatment of lower respiratory tract infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Pseudomonas aeruginosa, Haemophilus influenzae, Haemophilus parainfluenzae, or Streptococcus pneumoniae.* Also, Ciprofloxacin Aristo Injection, USP in 5% Dextrose is indicated for the treatment of acute exacerbations of chronic bronchitis caused by Moraxella catarrhalis.
Ciprofloxacin Aristo Injection, USP in 5% Dextrose is indicated in adult patients for treatment of nosocomial pneumonia caused by Haemophilus influenzae or Klebsiella pneumoniae.
Skin and Skin Structure Infections
Ciprofloxacin Aristo Injection, USP in 5% Dextrose is indicated in adult patients for treatment of skin and skin structure infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Morganella morganii, Citrobacter freundii, Pseudomonas aeruginosa, methicillin susceptible Staphylococcus aureus, methicillin-susceptible Staphylococcus epidermidis, or Streptococcus pyogenes.
Bone and Joint Infections
Ciprofloxacin Aristo Injection, USP in 5% Dextrose is indicated in adult patients for treatment of bone and joint infections caused by Enterobacter cloacae, Serratia marcescens, or Pseudomonas aeruginosa.
Complicated Intra-Abdominal Infections
Ciprofloxacin Aristo Injection, USP in 5% Dextrose is indicated in adult patients for treatment of complicated intra-abdominal infections (used in combination with metronidazole) caused by Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, or Bacteroides fragilis.
Ciprofloxacin Aristo Injection, USP in 5% Dextrose is indicated in adult patients for treatment of acute sinusitis caused by Haemophilus influenzae, Streptococcus pneumoniae, or Moraxella catarrhalis.
Chronic Bacterial Prostatitis
Ciprofloxacin Aristo Injection, USP in 5% Dextrose is indicated in adult patients for treatment of chronic bacterial prostatitis caused by Escherichia coli or Proteus mirabilis.
Empirical Therapy for Febrile Neutropenic Patients
Ciprofloxacin Aristo Injection, USP in 5% Dextrose is indicated in adult patients for the treatment of febrile neutropenia in combination with piperacillin sodium.
Complicated Urinary Tract Infections and Pyelonephritis
Ciprofloxacin Aristo Injection, USP in 5% Dextrose is indicated in pediatric patients one to 17 years of age for treatment of complicated urinary tract infections (cUTI) and pyelonephritis due to Escherichia coli.
Inhalational Anthrax (post-exposure)
Ciprofloxacin Aristo Injection, USP in 5% Dextrose is indicated in adults and pediatric patients from birth to 17 years of age for treatment of inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis.
Ciprofloxacin Aristo serum concentrations achieved in humans served as a surrogate endpoint reasonably likely to predict clinical benefit and provided the initial basis for approval of this indication.1 Supportive clinical information for Ciprofloxacin Aristo for anthrax post-exposure prophylaxis was obtained during the anthrax bioterror attacks of October 2001.
Ciprofloxacin Aristo Injection, USP in 5% Dextrose is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients from birth to 17 years of age. Efficacy studies of Ciprofloxacin Aristo could not be conducted in humans with plague for feasibility reasons. Therefore this indication is based on an efficacy study conducted in animals only.
Limitations of Use
Use in Pediatric Patients
Although effective in clinical trials, Ciprofloxacin Aristo is not a drug of first choice in the pediatric population due to an increased incidence of adverse events compared to controls, including events related to joints and/or surrounding tissues. Ciprofloxacin Aristo Injection, USP in 5% Dextrose, like other fluoroquinolones, is associated with arthropathy and histopathological changes in weight-bearing joints of juvenile animals.
Lower Respiratory Tract Infections
Ciprofloxacin Aristo Injection, USP in 5% Dextrose is not a drug of first choice in the treatment of presumed or confirmed pneumonia secondary to Streptococcus pneumoniae.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ciprofloxacin Aristo Injection, USP in 5% Dextrose and other antibacterial drugs, Ciprofloxacin Aristo Injection, USP in 5% Dextrose should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
If anaerobic organisms are suspected of contributing to the infection, appropriate therapy should be administered. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to Ciprofloxacin Aristo. Therapy with Ciprofloxacin Aristo Injection, USP in 5% Dextrose may be initiated before results of these tests are known; once results become available appropriate therapy should be continued. As with other drugs, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with Ciprofloxacin Aristo. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance.
How should I use Ciprofloxacin Aristo?
Use Ciprofloxacin Aristo suspension as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Ciprofloxacin Aristo suspension comes with an extra patient information sheet called a Medication Guide. Read it carefully. Read it again each time you get Ciprofloxacin Aristo suspension refilled.
- An extra patient leaflet may be available with Ciprofloxacin Aristo suspension. Talk to your pharmacist if you have questions about this information.
- Take Ciprofloxacin Aristo suspension by mouth with or without food. The preferred dosing time is 2 hours after a meal.
- Shake well before each use.
- Use a measuring device marked for medicine dosing. Ask your pharmacist for help if you are unsure of how to measure your dose.
- Take Ciprofloxacin Aristo suspension with a full glass of water (8 oz [240 mL]).
- Drinking extra fluids while you are taking Ciprofloxacin Aristo suspension is recommended. Check with your doctor for instructions.
- If you also take any products containing magnesium, aluminum, calcium, iron, or zinc (eg, antacids, quinapril, vitamins/minerals); didanosine; sucralfate; or bismuth subsalicylate, do not take them within 6 hours before or 2 hours after taking Ciprofloxacin Aristo suspension. Check with your doctor if you have questions.
- If you also take sevelamer, do not take it within 4 hours before or after taking Ciprofloxacin Aristo suspension. Check with your doctor if you have questions.
- Ciprofloxacin Aristo suspension works best if it is taken at the same time each day.
- To clear up your infection completely, take Ciprofloxacin Aristo suspension for the full course of treatment. Keep taking it even if you feel better in a few days.
- Avoid taking Ciprofloxacin Aristo suspension with milk or milk products (eg, calcium-enriched juice, yogurt) by themselves. However, taking Ciprofloxacin Aristo suspension as part of a full meal that contains milk or milk products is permitted.
- Do not miss any doses. If you miss a dose of Ciprofloxacin Aristo suspension, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Ciprofloxacin Aristo suspension.
Uses of Ciprofloxacin Aristo in details
Ciprofloxacin Aristo is used to treat wide range of bacterial infections including lung or respiratory tract infections, eye infection, bladder and kidney infections, reproductive tract infections, skin and soft tissue infections and bone and joint infections.
Ciprofloxacin Aristo description
Ciprofloxacin Aristo is a drug used to treat bacterial infections. It is a second generation fluoroquinolone antibacterial. It kills bacteria by interfering with the enzymes that cause DNA to rewind after being copied, which stops DNA and protein synthesis.
Ciprofloxacin Aristo is marketed worldwide with over three hundred different brand names. In the United States, Canada and the UK, it is marketed as Ciloxan, Ciprofloxacin Aristo, Ciprofloxacin Aristo XR, Ciprofloxacin Aristo XL Ciproxin and, most recently, Proquin. In Mexico it is available over the counter and marketed under the names Ciproflox or Ciprofloxacino. In Ecuador it is available and marketed under the name Cidrax. In Nigeria it is sold as Ciprotab while in Bangladesh it is marketed as Tablets and Microcapsules for Suspension by numerous companies, one of which is by Edruc Limited as Cipron. Additionally, Ciprofloxacin Aristo is available as a generic drug under a variety of different brand names and is also available for limited use in veterinary medicine.
Ciprofloxacin Aristo was first patented in 1983 by Bayer A.G. and subsequently approved by the United States Food and Drug Administration (FDA) in 1987.Ciprofloxacin Aristo has 12 F.D.A.-approved human uses and other veterinary uses, but it is often used for non-approved uses (off-label).
Ciprofloxacin Aristo interacts with other drugs, herbal and natural supplements, and thyroid medications.
Active ingredient matches for Ciprofloxacin Aristo:
Ciprofloxacin in Germany.
- DailyMed. "CIPROFLOXACIN; DEXAMETHASONE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailymed/se... (accessed September 18, 2017).
- Wikipedia. "ciprofloxacin: Link to the compound information in Wikipedia.". https://en.wikipedia.org/wiki/Ciprofloxa... (accessed September 18, 2017).
- PubChem. "ciprofloxacin". https://pubchem.ncbi.nlm.nih.gov/compoun... (accessed September 18, 2017).
- FDA Orange Book. "CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE: The publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the List, commonly known as the Orange Book), identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (the Act).". https://www.fda.gov/Drugs/InformationOnD... (accessed September 18, 2017).
ReviewsThe results of a survey conducted on ndrugs.com for Ciprofloxacin Aristo are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Ciprofloxacin Aristo. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
Consumer reported usefulNo survey data has been collected yet
Consumer reported price estimatesNo survey data has been collected yet
Consumer reported time for resultsNo survey data has been collected yet
Consumer reported ageNo survey data has been collected yet